Navigation Links
Perrigo Company Announces Launch of Clobetasol Propionate Foam
Date:3/20/2008

ALLEGAN, Mich., March 20 /PRNewswire-FirstCall/ -- Perrigo Company (Nasdaq: PRGO; TASE) today announced that the United States District Court for the District of New Jersey has denied Connetics Corporation's motion for a preliminary injunction related to Perrigo's Clobetasol Propionate Foam, the AB-rated generic equivalent to Connetics' Olux(R) Foam and has lifted the temporary restraints that have prevented Perrigo from launching the product. The Court also denied Perrigo's motion for Summary Judgment based on non- infringement. The case will now proceed to trial with the trial date not having been set.

With the temporary restraints lifted, Perrigo has commenced launching the product. As the first filer, this commences its 180 days of generic exclusivity.

Perrigo's Chairman and CEO Joseph C. Papa stated, "We are excited about the launch of Clobetasol Foam, which reflects our on-going efforts to make quality healthcare more affordable for our customers."

Clobetasol Propionate Foam is a topical corticosteroid indicated for the treatment of moderate to severe dermatosis of the scalp. Sales for the brand, Olux(R) Foam, 0.05%, were approximately $85 million according to Wolters Kluwer data for the 12 months ending January 2008.

Perrigo Company is a leading global healthcare supplier that develops, manufactures and distributes over-the-counter (OTC) and prescription pharmaceuticals, nutritional products, active pharmaceutical ingredients (API) and consumer products. The Company is the world's largest manufacturer of OTC pharmaceutical products for the store brand market. The Company's primary markets and locations of manufacturing facilities are the United States, Israel, Mexico and the United Kingdom. Visit Perrigo
'/>"/>

SOURCE Perrigo Company
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine news :

1. Perrigo Vice Chair Mori Arkin To Retire After 30 Years of Service
2. Perrigo Company to Host Analyst Meeting on September 18, 2007
3. Perrigo Company Announces FDA Approval for Ciclopirox Topical Solution
4. Perrigo Company Announces FDA Approval for Ciclopirox Topical Solution
5. Perrigo Confirms Filing for Generic Version of Mucinex(R) and Announcement of Lawsuit by Adams Respiratory
6. Perrigo Company Will Release First Quarter Fiscal 2008 Results on November 1, 2007
7. Perrigo Company Announces Dividend Increase
8. Perrigo Announces that Dexcels Settlement with AstraZeneca Allows OTC Omeprazole Launch Following Final FDA Approval
9. Perrigo Company to Present at The 26th Annual JPMorgan Healthcare Conference
10. Perrigo Acquires UK OTC Store Brand Supplier
11. Perrigo Company Authorizes Continuation of Share Repurchase Program and Announces Quarterly Dividend
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2015)... Baltimore, MD (PRWEB) , ... August 28, 2015 , ... ... reduction system from Merz, received FDA clearance for results that last for two ... clearance is exciting news for patients who are looking for a long-lasting, effective solution ...
(Date:8/28/2015)... ... August 28, 2015 , ... Saint Petersburg, FL —Pocket ... zero fat, carbs, sugar, gluten, lactose or caffeine in a convenient 2 oz. ... SupplySide CPG Editor’s Choice Awards. , Five consumer packaged goods (CPG) products were ...
(Date:8/28/2015)... Neb. (PRWEB) , ... August 28, 2015 , ... Medical ... the 2015 Best Places to Work in Healthcare by Modern Healthcare and ... , Now in its eighth year, the Best Places to Work in ...
(Date:8/28/2015)... ... 28, 2015 , ... SmartPractice Calendars afford dental ... practice contact information and logos, Calendars stand alone as functional brand-building giveaways ... seasonal mailings, thank you and welcome communications, and to complement statements and invoices. ...
(Date:8/28/2015)... ... August 28, 2015 , ... SharkNinja, ... with coffee connoisseur and Emmy-nominated actress, Sofia Vergara, and unveil the Ninja® ... Flavor Extraction™ technology, which delivers a variety of sizes and styles while achieving ...
Breaking Medicine News(10 mins):Health News:Maryland Dermatologists Discuss Non-Invasive Cellulite Reduction System Cellfina Receiving 2-Year FDA Clearance 2Health News:Maryland Dermatologists Discuss Non-Invasive Cellulite Reduction System Cellfina Receiving 2-Year FDA Clearance 3Health News:Pocket Protein™ Named 2015 CPG Editor’s Choice Award Finalist by Informa’s SupplySide 2Health News:Pocket Protein™ Named 2015 CPG Editor’s Choice Award Finalist by Informa’s SupplySide 3Health News:Medical Solutions Recognized as One of 2015 Best Places to Work in Healthcare 2Health News:Medical Solutions Recognized as One of 2015 Best Places to Work in Healthcare 3Health News:SmartPractice® Introduces 2016 Calendars for Dental Practice Giveaways 2Health News:Sofia Vergara Partners With SharkNinja® To Launch The Ninja Coffee Bar™ 2Health News:Sofia Vergara Partners With SharkNinja® To Launch The Ninja Coffee Bar™ 3
... new computerised screening test for cervical cancer detects more ... a study published on bmj.com today. ,It ... re-tested and might allow for longer intervals in-between testing, ... screening of conventional pap smears for cervical cancer has ...
... perception of older drivers tends to be negative, write ... aged more than 80 consistently show prudent driving behaviours. ... friends, and services and is an independent risk factor ... changes to UK licensing rules should therefore try to ...
... dead'. ,Hackers have disguised the PC worm as ... up-coming book, out on July 21. ,The virus ... drives plugged into computers where users have unwittingly downloaded the ... time the device is inserted. ,Its other effects ...
... has dosed its first patient in a 60-patient Phase ... glutathione peroxidase mimetic, in diabetic patients with a ... for cardiovascular complications. , This dose escalating ... inflammatory cardiovascular biomarkers in patients with an elevated risk ...
... Bayer HealthCare Pharmaceuticals Inc. (NYSE: BAY) and Onyx Pharmaceuticals, ... Drug Application (sNDA) for Nexavar(R) (sorafenib) tablets has ... (FDA) for the treatment of patients with hepatocellular carcinoma ... ,Nexavar is currently approved in more than 50 ...
... Craig Venter Institute (JCVI) today announced the results of ... one type of bacteria into another type dictated by ... online in the journal Science, by JCVI's Carole Lartigue, ... to change one bacterial species, Mycoplasma capricolum into another, ...
Cached Medicine News:Health News:New Cervical Cancer Test Increases the Detection Rate of Abnormal Cells 2Health News:Alteon Initiates Phase 2 Trial of ALT-2074 in Diabetes and Haptoglobin 2-2 2Health News:Bayer and Onyx Submit Supplemental New Drug Application for Nexavar to Treat Liver Cancer 2Health News:First Bacterial Genome Transplantation Changing One Species to Another 2
(Date:8/28/2015)... N.J. , Aug. 28, 2015  IP Shakti, LLC, ... LLC. ... "Our new corporate identity signifies our transformation ... world,s first predictive analytics platform for patent claim validity." ... the launch of the proprietary AIA Shield™ platform, the Company ...
(Date:8/28/2015)... PITTSBURGH , Aug. 28, 2015  Mylan ... its shareholders have approved Mylan,s proposed acquisition of ... and the related issuance of Mylan ordinary shares ... of shareholders held today. The transaction received the ... general meeting. In addition, the transaction received support ...
(Date:8/28/2015)... , August 28, 2015 Insights- ... seamlessly connects people, technologies and care protoc ols across ... and the cost of healthcare delivery   ... presence at  ESC Congress 2015 , where the company is ... EchoNavigator and IntelliSpace Cardiovascular, that connect people and technology with ...
Breaking Medicine Technology:IP Shakti, LLC Changes Company Name to Prediqtus, LLC 2Mylan Shareholders Overwhelmingly Approve Proposed Acquisition of Perrigo 2Mylan Shareholders Overwhelmingly Approve Proposed Acquisition of Perrigo 3Mylan Shareholders Overwhelmingly Approve Proposed Acquisition of Perrigo 4Mylan Shareholders Overwhelmingly Approve Proposed Acquisition of Perrigo 5Mylan Shareholders Overwhelmingly Approve Proposed Acquisition of Perrigo 6Mylan Shareholders Overwhelmingly Approve Proposed Acquisition of Perrigo 7Mylan Shareholders Overwhelmingly Approve Proposed Acquisition of Perrigo 8Mylan Shareholders Overwhelmingly Approve Proposed Acquisition of Perrigo 9Philips Showcases New Integrated Cardiology Solutions to Advance Minimally Invasive Procedures at ESC Congress 2015 2Philips Showcases New Integrated Cardiology Solutions to Advance Minimally Invasive Procedures at ESC Congress 2015 3Philips Showcases New Integrated Cardiology Solutions to Advance Minimally Invasive Procedures at ESC Congress 2015 4
... Palatin Technologies,Inc. (AMEX: PTN ) announced today ... trial of PL-3994, a long acting analog of ... decompensated congestive,heart failure (CHF). The trial is being ... to the U.S. Food and Drug,Administration. Future plans ...
... Third Quarter 2007 Earnings release, you are,invited to listen to ... on Tuesday, November 6, 2007 at 9:30 a.m. EST, with ... Chief,Financial Officer. What: QIAGEN N.V. ... Tuesday, November 6, 2007 at 9:30 a.m. EST, ...
Cached Medicine Technology:Palatin Technologies, Inc. Reports Initiation of Human Trials for the Treatment of Congestive Heart Failure 2Palatin Technologies, Inc. Reports Initiation of Human Trials for the Treatment of Congestive Heart Failure 3QIAGEN N.V. (Nasdaq: QGEN) Invites You to Join Its Third Quarter 2007 Earnings Conference Call on the Web 2
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
Medicine Products: